61346-19-8 Usage
Uses
Used in Pharmaceutical and Agrochemical Industries:
1,2-Dihydro-5-nitroindazol-3-one is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals due to its unique chemical properties and reactivity.
Used in Scientific Research:
1,2-Dihydro-5-nitroindazol-3-one is used as a tool in scientific research for studying the effects of certain chemical reactions, particularly its mutagenic properties, which can provide valuable insights into the mechanisms of genetic mutations and their implications in various biological processes.
Synthesis Methods:
1,2-Dihydro-5-nitroindazol-3-one can be synthesized through various methods, including the nitration of indazole derivatives or the reduction of nitroindazole compounds. These methods allow for the production of 1,2-DIHYDRO-5-NITROINDAZOL-3-ONE in a controlled and efficient manner, facilitating its use in various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 61346-19-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,3,4 and 6 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 61346-19:
(7*6)+(6*1)+(5*3)+(4*4)+(3*6)+(2*1)+(1*9)=108
108 % 10 = 8
So 61346-19-8 is a valid CAS Registry Number.
InChI:InChI=1/C7H5N3O3/c11-7-5-3-4(10(12)13)1-2-6(5)8-9-7/h1-3H,(H2,8,9,11)
61346-19-8Relevant academic research and scientific papers
NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
-
Page/Page column 40-41, (2012/12/13)
This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.
BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
-
Page/Page column 129-130, (2008/12/07)
The present invention provides novel bicyclic lactams derivatives, and analogues thereof, of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, B, C, W, Y, Z1, Z2, Z3, Z4, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.